Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies

Background: BRAF (v-raf murine sarcoma viral oncogene homolog B1) and MEK (mitogen activated protein kinase) inhibitors, as well as immunotherapy against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1), have shown good resul...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Med
Main Authors: Dika, Emi, Lambertini, Martina, Gouveia, Bruna, Mussi, Martina, Marcelli, Emanuela, Campione, Elena, Gurioli, Carlotta, Melotti, Barbara, Alessandrini, Aurora, Ribero, Simone
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2021
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8003791/
https://ncbi.nlm.nih.gov/pubmed/33808846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10061283
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares